vs

Side-by-side financial comparison of BXP, Inc. (BXP) and Charles River Laboratories (CRL). Click either name above to swap in a different company.

Charles River Laboratories is the larger business by last-quarter revenue ($994.2M vs $872.1M, roughly 1.1× BXP, Inc.). BXP, Inc. runs the higher net margin — 15.3% vs -27.8%, a 43.1% gap on every dollar of revenue. On growth, BXP, Inc. posted the faster year-over-year revenue change (0.8% vs -0.8%). Over the past eight quarters, BXP, Inc.'s revenue compounded faster (1.3% CAGR vs -0.9%).

BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

BXP vs CRL — Head-to-Head

Bigger by revenue
CRL
CRL
1.1× larger
CRL
$994.2M
$872.1M
BXP
Growing faster (revenue YoY)
BXP
BXP
+1.6% gap
BXP
0.8%
-0.8%
CRL
Higher net margin
BXP
BXP
43.1% more per $
BXP
15.3%
-27.8%
CRL
Faster 2-yr revenue CAGR
BXP
BXP
Annualised
BXP
1.3%
-0.9%
CRL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BXP
BXP
CRL
CRL
Revenue
$872.1M
$994.2M
Net Profit
$133.0M
$-276.6M
Gross Margin
Operating Margin
-28.5%
Net Margin
15.3%
-27.8%
Revenue YoY
0.8%
-0.8%
Net Profit YoY
53.0%
-28.9%
EPS (diluted)
$1.69
$-5.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BXP
BXP
CRL
CRL
Q1 26
$872.1M
Q4 25
$877.1M
$994.2M
Q3 25
$871.5M
$1.0B
Q2 25
$868.5M
$1.0B
Q1 25
$865.2M
$984.2M
Q4 24
$858.6M
$1.0B
Q3 24
$859.2M
$1.0B
Q2 24
$850.5M
$1.0B
Net Profit
BXP
BXP
CRL
CRL
Q1 26
$133.0M
Q4 25
$248.4M
$-276.6M
Q3 25
$-121.7M
$54.4M
Q2 25
$89.0M
$52.3M
Q1 25
$61.2M
$25.5M
Q4 24
$-228.9M
$-214.5M
Q3 24
$83.6M
$69.7M
Q2 24
$79.6M
$94.1M
Gross Margin
BXP
BXP
CRL
CRL
Q1 26
Q4 25
58.8%
Q3 25
59.3%
Q2 25
59.2%
Q1 25
59.2%
Q4 24
59.7%
Q3 24
59.5%
34.6%
Q2 24
59.8%
34.5%
Operating Margin
BXP
BXP
CRL
CRL
Q1 26
Q4 25
-28.5%
Q3 25
13.3%
Q2 25
9.7%
Q1 25
7.6%
Q4 24
-16.7%
Q3 24
11.6%
Q2 24
14.8%
Net Margin
BXP
BXP
CRL
CRL
Q1 26
15.3%
Q4 25
28.3%
-27.8%
Q3 25
-14.0%
5.4%
Q2 25
10.2%
5.1%
Q1 25
7.1%
2.6%
Q4 24
-26.7%
-21.4%
Q3 24
9.7%
6.9%
Q2 24
9.4%
9.2%
EPS (diluted)
BXP
BXP
CRL
CRL
Q1 26
$1.69
Q4 25
$1.56
$-5.57
Q3 25
$-0.77
$1.10
Q2 25
$0.56
$1.06
Q1 25
$0.39
$0.50
Q4 24
$-1.46
$-4.17
Q3 24
$0.53
$1.33
Q2 24
$0.51
$1.74

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BXP
BXP
CRL
CRL
Cash + ST InvestmentsLiquidity on hand
$512.8M
$213.8M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$7.7B
$3.2B
Total Assets
$25.1B
$7.1B
Debt / EquityLower = less leverage
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BXP
BXP
CRL
CRL
Q1 26
$512.8M
Q4 25
$1.5B
$213.8M
Q3 25
$861.1M
$207.1M
Q2 25
$447.0M
$182.8M
Q1 25
$398.1M
$229.4M
Q4 24
$1.3B
$194.6M
Q3 24
$1.4B
$210.2M
Q2 24
$685.4M
$179.2M
Total Debt
BXP
BXP
CRL
CRL
Q1 26
Q4 25
$2.1B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.5B
Q4 24
$2.2B
Q3 24
$2.3B
Q2 24
$2.4B
Stockholders' Equity
BXP
BXP
CRL
CRL
Q1 26
$7.7B
Q4 25
$5.1B
$3.2B
Q3 25
$5.0B
$3.4B
Q2 25
$5.3B
$3.4B
Q1 25
$5.3B
$3.2B
Q4 24
$5.4B
$3.5B
Q3 24
$5.8B
$3.8B
Q2 24
$5.8B
$3.7B
Total Assets
BXP
BXP
CRL
CRL
Q1 26
$25.1B
Q4 25
$26.2B
$7.1B
Q3 25
$26.0B
$7.5B
Q2 25
$25.6B
$7.6B
Q1 25
$25.4B
$7.6B
Q4 24
$26.1B
$7.5B
Q3 24
$26.4B
$8.0B
Q2 24
$25.5B
$7.9B
Debt / Equity
BXP
BXP
CRL
CRL
Q1 26
Q4 25
0.68×
Q3 25
0.64×
Q2 25
0.70×
Q1 25
0.79×
Q4 24
0.65×
Q3 24
0.62×
Q2 24
0.65×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BXP
BXP
CRL
CRL
Operating Cash FlowLast quarter
$147.5M
Free Cash FlowOCF − Capex
$58.6M
FCF MarginFCF / Revenue
5.9%
Capex IntensityCapex / Revenue
1.5%
8.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$518.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BXP
BXP
CRL
CRL
Q1 26
Q4 25
$407.8M
$147.5M
Q3 25
$274.2M
$213.8M
Q2 25
$353.1M
$204.6M
Q1 25
$210.0M
$171.7M
Q4 24
$383.7M
$159.4M
Q3 24
$286.1M
$251.8M
Q2 24
$367.1M
$193.5M
Free Cash Flow
BXP
BXP
CRL
CRL
Q1 26
Q4 25
$362.7M
$58.6M
Q3 25
$231.6M
$178.2M
Q2 25
$281.5M
$169.3M
Q1 25
$152.6M
$112.4M
Q4 24
$312.5M
$83.7M
Q3 24
$234.5M
$213.1M
Q2 24
$332.4M
$154.0M
FCF Margin
BXP
BXP
CRL
CRL
Q1 26
Q4 25
41.4%
5.9%
Q3 25
26.6%
17.7%
Q2 25
32.4%
16.4%
Q1 25
17.6%
11.4%
Q4 24
36.4%
8.4%
Q3 24
27.3%
21.1%
Q2 24
39.1%
15.0%
Capex Intensity
BXP
BXP
CRL
CRL
Q1 26
1.5%
Q4 25
5.1%
8.9%
Q3 25
4.9%
3.5%
Q2 25
8.2%
3.4%
Q1 25
6.6%
6.0%
Q4 24
8.3%
7.5%
Q3 24
6.0%
3.8%
Q2 24
4.1%
3.8%
Cash Conversion
BXP
BXP
CRL
CRL
Q1 26
Q4 25
1.64×
Q3 25
3.93×
Q2 25
3.97×
3.91×
Q1 25
3.43×
6.74×
Q4 24
Q3 24
3.42×
3.61×
Q2 24
4.61×
2.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BXP
BXP

Lease$818.2M94%
Parking and other$30.8M4%
Development and management services$9.2M1%

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

Related Comparisons